Biotech | December 24, 2025
Enveda launches Phase 1 trial for first-in-class Oral IBD therapy
The Phase 1 study will evaluate the safety, tolerability, and pharmacokinetics (PK) of ENV-6946 in healthy volunteers
The Phase 1 study will evaluate the safety, tolerability, and pharmacokinetics (PK) of ENV-6946 in healthy volunteers
Finerenone is the first therapy targeting the mineralocorticoid receptor pathway to demonstrate cardiovascular benefits in heart failure patients
The company also reported significant progress toward its internally defined Sustainable Development Goals
SGX945 delivered beneficial effects in 7 of 8 patients suffering from painful oral ulcers
The expansion includes a larger technical and service team and increased local procurement
This recognition demonstrate excellence in intellectual property (IP) value creation.
The move strengthens GBL’s clinical-stage presence in the United States
India plays a critical role in Bristol Myers Squibb’s global strategy
The Signals Xynthetica solution brings AI-driven in-silico generation, predictive modeling, and experimental validation into a single, governed environment
This launch is part of the company's strategy to expand its nutraceutical portfolio
Subscribe To Our Newsletter & Stay Updated
